Journal of Genetic Medicine

Korean Society of Medical Genetics and Genomics (대한의학유전학회)
권호 표지
DOI QR코드

DOI QR Code

Mitophagy stimulation as a novel strategy for the treatment of mitochondrial diseases

  • Kang-Min Lee (Department of Biochemistry, College of Medicine, Dong-A University) ;
  • Jeanho Yun (Department of Biochemistry, College of Medicine, Dong-A University)
  • Received : 2022.11.21
  • Accepted : 2022.12.21
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Mitophagy, the selective degradation of damaged or surplus mitochondria using core autophagy machinery, plays an essential role in maintaining cellular mitochondrial function. Impaired mitophagy is closely linked to various human diseases, including neurodegenerative diseases, cardiovascular diseases, cancers and kidney disease. Defective mitophagy induces the accumulation of damaged mitochondria and thereby results in a decline in cellular survival and tissue function. Accordingly, enhancement of mitophagy has been proposed as a novel strategy for the treatment of human diseases closely linked to mitochondrial dysfunction. Recent studies showing that the stimulation of mitophagy has a therapeutic effect on several disease models highlight the possibility of disease treatment using mitophagy. The development of mitophagy inducers with toxicity and the identification of molecular mechanisms will enable the clinical application of mitophagy-based treatments.

Keywords

Acknowledgement

I apologize to the authors whose work could not be referenced due to space limitations. This research was supported by National Research Foundation of Korea (NRF) grants funded by the Korea government (MSIT) (2022R1A2C1005336) and by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea (HU21C0107).

References

  1. Um JH, Yun J. Emerging role of mitophagy in human diseases and physiology. BMB Rep 2017;50:299-307. https://doi.org/10.5483/BMBRep.2017.50.6.056
  2. Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener 2020;15:30.
  3. Redmann M, Dodson M, Boyer-Guittaut M, Darley-Usmar V, Zhang J. Mitophagy mechanisms and role in human diseases. Int J Biochem Cell Biol 2014;53:127-33. https://doi.org/10.1016/j.biocel.2014.05.010
  4. Saito T, Hamano K, Sadoshima J. Molecular mechanisms and clinical implications of multiple forms of mitophagy in the heart. Cardiovasc Res 2021;117:2730-41. https://doi.org/10.1093/cvr/cvaa340
  5. Montava-Garriga L, Ganley IG. Outstanding questions in mitophagy: what we do and do not know. J Mol Biol 2020;432:206-30. https://doi.org/10.1016/j.jmb.2019.06.032
  6. Killackey SA, Philpott DJ, Girardin SE. Mitophagy pathways in health and disease. J Cell Biol 2020;219:e202004029.
  7. Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol 2018;20:1013-22. https://doi.org/10.1038/s41556-018-0176-2
  8. Rugarli EI, Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J 2012;31:1336-49. https://doi.org/10.1038/emboj.2012.38
  9. Fivenson EM, Lautrup S, Sun N, Scheibye-Knudsen M, Stevnsner T, Nilsen H, et al. Mitophagy in neurodegeneration and aging. Neurochem Int 2017;109:202-9. https://doi.org/10.1016/j.neuint.2017.02.007
  10. Deas E, Wood NW, Plun-Favreau H. Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta 2011;1813:623-33. https://doi.org/10.1016/j.bbamcr.2010.08.007
  11. Gao F, Yang J, Wang D, Li C, Fu Y, Wang H, et al. Mitophagy in Parkinson's disease: pathogenic and therapeutic implications. Front Neurol 2017;8:527.
  12. Hsieh CH, Shaltouki A, Gonzalez AE, Bettencourt da Cruz A, Burbulla LF, St Lawrence E, et al. Functional Impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson's disease. Cell Stem Cell 2016;19:709-24. https://doi.org/10.1016/j.stem.2016.08.002
  13. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006;441:1157-61. https://doi.org/10.1038/nature04788
  14. Katayama H, Hama H, Nagasawa K, Kurokawa H, Sugiyama M, Ando R, et al. Visualizing and modulating mitophagy for therapeutic studies of neurodegeneration. Cell 2020;181:1176-87.e16. https://doi.org/10.1016/j.cell.2020.04.025
  15. Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci 2019;22:401-12. https://doi.org/10.1038/s41593-018-0332-9
  16. Cummins N, Tweedie A, Zuryn S, Bertran-Gonzalez J, Gotz J. Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. EMBO J 2019;38:e99360.
  17. Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci 2017;40:151-66. https://doi.org/10.1016/j.tins.2017.01.002
  18. Chakravorty A, Jetto CT, Manjithaya R. Dysfunctional mitochondria and mitophagy as drivers of Alzheimer's disease pathogenesis. Front Aging Neurosci 2019;11:311.
  19. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011;68:1440-6.
  20. Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 2015;18:631-6. https://doi.org/10.1038/nn.4000
  21. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223-6. https://doi.org/10.1038/nature08971
  22. Sun N, Yun J, Liu J, Malide D, Liu C, Rovira II, et al. Measuring in vivo mitophagy. Mol Cell 2015;60:685-96. https://doi.org/10.1016/j.molcel.2015.10.009
  23. Hwang S, Disatnik MH, Mochly-Rosen D. Impaired GAPDH-induced mitophagy contributes to the pathology of Huntington's disease. EMBO Mol Med 2015;7:1307-26. https://doi.org/10.15252/emmm.201505256
  24. Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010;13:567-76. https://doi.org/10.1038/nn.2528
  25. Dutta D, Calvani R, Bernabei R, Leeuwenburgh C, Marzetti E. Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circ Res 2012;110:1125-38. https://doi.org/10.1161/CIRCRESAHA.111.246108
  26. Billia F, Hauck L, Konecny F, Rao V, Shen J, Mak TW. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. Proc Natl Acad Sci U S A 2011;108:9572-7. https://doi.org/10.1073/pnas.1106291108
  27. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007;13:619-24. https://doi.org/10.1038/nm1574
  28. Taneike M, Yamaguchi O, Nakai A, Hikoso S, Takeda T, Mizote I, et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 2010;6:600-6. https://doi.org/10.4161/auto.6.5.11947
  29. Kubli DA, Zhang X, Lee Y, Hanna RA, Quinsay MN, Nguyen CK, et al. Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction. J Biol Chem 2013;288:915-26. https://doi.org/10.1074/jbc.M112.411363
  30. Piquereau J, Godin R, Deschenes S, Bessi VL, Mofarrahi M, Hussain SN, et al. Protective role of PARK2/Parkin in sepsis-induced cardiac contractile and mitochondrial dysfunction. Autophagy 2013;9:1837-51. https://doi.org/10.4161/auto.26502
  31. Bravo-San Pedro JM, Kroemer G, Galluzzi L. Autophagy and mitophagy in cardiovascular disease. Circ Res 2017;120:1812-24. https://doi.org/10.1161/CIRCRESAHA.117.311082
  32. Luo H, Zhang R, Krigman J, McAdams A, Ozgen S, Sun N. A healthy heart and a healthy brain: looking at mitophagy. Front Cell Dev Biol 2020;8:294.
  33. Tong M, Sadoshima J. Mitochondrial autophagy in cardiomyopathy. Curr Opin Genet Dev 2016;38:8-15. https://doi.org/10.1016/j.gde.2016.02.006
  34. Saito T, Nah J, Oka SI, Mukai R, Monden Y, Maejima Y, et al. An alternative mitophagy pathway mediated by Rab9 protects the heart against ischemia. J Clin Invest 2019;129:802-19. https://doi.org/10.1172/JCI122035
  35. Tong M, Saito T, Zhai P, Oka SI, Mizushima W, Nakamura M, et al. Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. Circ Res 2019;124:1360-71. https://doi.org/10.1161/CIRCRESAHA.118.314607
  36. Tong M, Saito T, Zhai P, Oka SI, Mizushima W, Nakamura M, et al. Alternative mitophagy protects the heart against obesity-associated cardiomyopathy. Circ Res 2021;129:1105-21. https://doi.org/10.1161/CIRCRESAHA.121.319377
  37. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005;24:4421-32. https://doi.org/10.1038/sj.onc.1208642
  38. Fragoso MC, Almeida MQ, Mazzuco TL, Mariani BM, Brito LP, Goncalves TC, et al. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol 2012;166:61-7.
  39. Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, et al. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 2007;26:298-307. https://doi.org/10.1038/sj.onc.1209772
  40. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 2010;107:15145-50. https://doi.org/10.1073/pnas.1009941107
  41. Sun X, Liu M, Hao J, Li D, Luo Y, Wang X, et al. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle 2013;12:1133-41. https://doi.org/10.4161/cc.24215
  42. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010;42:77-82. https://doi.org/10.1038/ng.491
  43. Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y, et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008;27:6002-11. https://doi.org/10.1038/onc.2008.199
  44. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxiainducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004;64:5338-46. https://doi.org/10.1158/0008-5472.CAN-04-0089
  45. Fang EF, Kassahun H, Croteau DL, Scheibye-Knudsen M, Marosi K, Lu H, et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab 2016;24:566-81.
  46. Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, SenGupta T, Nilsen H, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 2014;157:882-96. https://doi.org/10.1016/j.cell.2014.03.026
  47. Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest 2012;122:3799-806. https://doi.org/10.1172/JCI58321
  48. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013;14:197-210. https://doi.org/10.1038/nrm3546
  49. Sumpter R Jr, Sirasanagandla S, Fernandez AF, Wei Y, Dong X, Franco L, et al. Fanconi anemia proteins function in mitophagy and immunity. Cell 2016;165:867-81. https://doi.org/10.1016/j.cell.2016.04.006
  50. Labuschagne CF, Cheung EC, Blagih J, Domart MC, Vousden KH. Cell clustering promotes a metabolic switch that supports metastatic colonization. Cell Metab 2019;30:720-34.e5. https://doi.org/10.1016/j.cmet.2019.07.014
  51. Pedanou VE, Gobeil S, Tabaries S, Simone TM, Zhu LJ, Siegel PM, et al. The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. Elife 2016;5:e16844. https://doi.org/10.7554/eLife.16844
  52. Salem AF, Al-Zoubi MS, Whitaker-Menezes D, Martinez-Outschoorn UE, Lamb R, Hulit J, et al. Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. Cell Cycle 2013;12:818-25. https://doi.org/10.4161/cc.23722
  53. Poole LP, Macleod KF. Mitophagy in tumorigenesis and metastasis. Cell Mol Life Sci 2021;78:3817-51. https://doi.org/10.1007/s00018-021-03774-1
  54. Ma X, McKeen T, Zhang J, Ding WX. Role and mechanisms of mitophagy in liver diseases. Cells 2020;9:837.
  55. Wang L, Liu X, Nie J, Zhang J, Kimball SR, Zhang H, et al. ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis. Hepatology 2015;61:486-96. https://doi.org/10.1002/hep.27420
  56. Yu X, Hao M, Liu Y, Ma X, Lin W, Xu Q, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol 2019;864:172715.
  57. Yu X, Xu Y, Zhang S, Sun J, Liu P, Xiao L, et al. Quercetin attenuates chronic ethanol-induced hepatic mitochondrial damage through enhanced mitophagy. Nutrients 2016;8:27.
  58. Zhou H, Zhu P, Wang J, Toan S, Ren J. DNA-PKcs promotes alcohol-related liver disease by activating Drp1-related mitochondrial fission and repressing FUNDC1-required mitophagy. Signal Transduct Target Ther 2019;4:56.
  59. Go KL, Lee S, Zendejas I, Behrns KE, Kim JS. Mitochondrial dysfunction and autophagy in hepatic ischemia/reperfusion injury. Biomed Res Int 2015;2015:183469.
  60. Kang JW, Choi HS, Lee SM. Resolvin D1 attenuates liver ischaemia/reperfusion injury through modulating thioredoxin 2-mediated mitochondrial quality control. Br J Pharmacol 2018;175:2441-53. https://doi.org/10.1111/bph.14212
  61. Ning XJ, Yan X, Wang YF, Wang R, Fan XL, Zhong ZB, et al. Parkin deficiency elevates hepatic ischemia/reperfusion injury accompanying decreased mitochondrial autophagy, increased apoptosis, impaired DNA damage repair and altered cell cycle distribution. Mol Med Rep 2018;18:5663-8.
  62. Wang Y, Cai J, Tang C, Dong Z. Mitophagy in acute kidney injury and kidney repair. Cells 2020;9:338.
  63. Zhang X, Feng J, Li X, Wu D, Wang Q, Li S, et al. Mitophagy in diabetic kidney disease. Front Cell Dev Biol 2021;9:778011.
  64. Chen K, Dai H, Yuan J, Chen J, Lin L, Zhang W, et al. Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy. Cell Death Dis 2018;9:105.
  65. Guo F, Wang W, Song Y, Wu L, Wang J, Zhao Y, et al. LncRNA SNHG17 knockdown promotes Parkin-dependent mitophagy and reduces apoptosis of podocytes through Mst1. Cell Cycle 2020;19:1997-2006. https://doi.org/10.1080/15384101.2020.1783481
  66. Sun J, Zhu H, Wang X, Gao Q, Li Z, Huang H. CoQ10 ameliorates mitochondrial dysfunction in diabetic nephropathy through mitophagy. J Endocrinol 2019, in press.
  67. Bhattacharya S, Yin J, Huo W, Chaum E. Modeling of mitochondrial bioenergetics and autophagy impairment in MELAS-mutant iPSC-derived retinal pigment epithelial cells. Stem Cell Res Ther 2022;13:260.
  68. Song YM, Lee WK, Lee YH, Kang ES, Cha BS, Lee BW. Metformin restores Parkin-mediated mitophagy, suppressed by cytosolic p53. Int J Mol Sci 2016;17:122.
  69. Johnson SC, Yanos ME, Kayser EB, Quintana A, Sangesland M, Castanza A, et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 2013;342:1524-8. https://doi.org/10.1126/science.1244360
  70. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-22.
  71. Eisenberg T, Abdellatif M, Schroeder S, Primessnig U, Stekovic S, Pendl T, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med 2016;22:1428-38. https://doi.org/10.1038/nm.4222
  72. Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Felix AA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med 2016;22:879-88.
  73. Gao H, Lv Y, Liu Y, Li J, Wang X, Zhou Z, et al. Wolfberry-derived zeaxanthin dipalmitate attenuates ethanol-induced hepatic damage. Mol Nutr Food Res 2019;63:e1801339.
  74. Gong LL, Yang S, Zhang W, Han FF, Lv YL, Wan ZR, et al. Akebia saponin D alleviates hepatic steatosis through BNip3 induced mitophagy. J Pharmacol Sci 2018;136:189-95. https://doi.org/10.1016/j.jphs.2017.11.007
  75. Lin D, He H, Ji H, Willis J, Willard L, Jiang Y, et al. Wolfberries potentiate mitophagy and enhance mitochondrial biogenesis leading to prevention of hepatic steatosis in obese mice: the role of AMP-activated protein kinase α2 subunit. Mol Nutr Food Res 2014;58:1005-15. https://doi.org/10.1002/mnfr.201300186
  76. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011;14:528-36. https://doi.org/10.1016/j.cmet.2011.08.014
  77. Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003;14:e3.
  78. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006;144:337-43. https://doi.org/10.7326/0003-4819-144-5-200603070-00008
  79. Meyer N, Zielke S, Michaelis JB, Linder B, Warnsmann V, Rakel S, et al. AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells. Autophagy 2018;14:1693-709. https://doi.org/10.1080/15548627.2018.1476812
  80. Wallace DC, Chalkia D. Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harb Perspect Biol 2013;5:a021220.
  81. Villanueva Paz M, Cotan D, Garrido-Maraver J, Cordero MD, Oropesa-Avila M, de La Mata M, et al. Targeting autophagy and mitophagy for mitochondrial diseases treatment. Expert Opin Ther Targets 2016;20:487-500. https://doi.org/10.1517/14728222.2016.1101068
  82. Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ. Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc Natl Acad Sci U S A 2010;107:11835-40. https://doi.org/10.1073/pnas.0914569107
  83. Cen X, Chen Y, Xu X, Wu R, He F, Zhao Q, et al. Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer's disease mouse model. Nat Commun 2020;11:5731.
  84. Xie C, Zhuang XX, Niu Z, Ai R, Lautrup S, Zheng S, et al. Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat Biomed Eng 2022;6:76-93. https://doi.org/10.1038/s41551-021-00819-5